Caplight Directory>Companies>Inverna Therapeutics-preview>Invernatx


Inverna Therapeutics

Inverna Therapeutics

Private
OdenseHealthcare & Life Scienceshttps://www.invernatx.com/

Last Round

Grant

Oct 9, 2025

Momentum Score

25 /100

Company Overview

Inverna Therapeutics is a biotechnology company that is a developer of a next-generation ribonucleic acid splicing modulation platform intended to transform patient outcomes in severe genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

RNA splicing modulationoligonucleotide therapypseudo-exon activationantisense oligonucleotideASOsplice switchingHuntington's diseaseParkinson's diseaseRNA therapyneurodegenerative diseasedrug discovery platformgenetic diseaseallele-specific targetingLRRK2 targetpre-clinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Inverna Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Inverna Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
GrantOct 9, 2025
SeedJan 7, 2025
View all Funding Rounds

Key People

Founding team and executive leadership

Poul Sørensen

CEO

Executive Team

Inverna Therapeutics Investors

Notable investors and investment history

InvestorRounds
University of Southern DenmarkSeed
The Michael J. Fox Foundation for Parkinson's ResearchGrant
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors increased 139% MoM.

  • Oct 9, 2025

    Received grant from The Michael J. Fox Foundation.

View all signals

Inverna Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Inverna Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Inverna Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOdense
Employee Range6
Year Founded2024
Last FundingOct 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.